SESSION 1 – INTEGRATIVE RADIOTHERAPY 23rd, 08:45 - 11:30

Dan G. Duda, Combining Stroma-Targeted Therapies with Radiation to Prevent Resistance
Jens Overgaard, Intratumoral Heterogeneity: Hypoxia and Radiotherapy
Gillies McKenna, The Tumour Microenvironment in Radiotherapy: Approaches to the Problem
Jürgen Debus, HITting the Target

SESSION 2 – DRUGGING THE CANCER GENOME 23rd, 11:30 - 16:30

William Hahn, Functional Genomics, Experimental Models and Cancer
David Gonzalez, Molecular Stratification of Cancer in the Clinical Setting
Brian Huntly, Altered Transcriptional and Epigenetic Control in Acute Myeloid Leukemia: Mechanisms and Novel Therapeutics
Mathew Garnett, Discovery of Drug Sensitizing Genotypes in Cancer Cells
Mario Capecchi, Modeling Human Cancers in the Mouse
Ugur Sahin, Towards Individualized Immunotherapy
Klaus Pantel, “Liquid Biopsy” Current Status and Future Perspective
Nils Cordes, Beyond the CENTRIC Trial – Integrating Targeting for Tumor Therapy Sensitization

SESSION 3 – INNOVATIVE ANTI-CANCER Targets 24th, 08:00 - 11:30

Rolf Bjerkvig, Adaptive Mechanisms to Anti-Vascular Therapy
Patrick Wen, Novel Targets and Strategies in Gliomas
W. K. Alfred Yung, Targeting PI3k Pathway Resistance in Glioblastoma
Thomas Würdinger, Novel Therapeutic Interventions in Glioblastoma
Stefan Pfister, New Therapeutic Targets in Childhood Brain Tumors
Matthias Mann, The Modern MS-Based Proteomics Toolbox and its Application in Cancer

SESSION 4 – ANTI-CANCER IMMUNOTHERAPY 24th, 11:30 - 16:00

Robert Schreiber, Cancer Immunodediting and a Genomics Approach to Cancer Immunotherapy
Hans-Georg Rammensee, Towards Personalized Immunotherapy of Cancer
Cornelis Melief, Towards more Efficient Immunotherapy of Established Lesions Caused by High-Risk HPV
Steve Feldman, Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells
George Prendergast, Cancer Immunomodulation: IDO Pathway and its Therapeutic Correction
Klaus Bosslet, Manipulation of the Tumor Micro Environment by Depletion of Tumor Associated Macrophages
Gail Lewis Phillips, Multiple Strategies for Targeting HER2-Positive Breast Cancer

SESSION 5 – PREVENTION & EARLY CANCER DETECTION 24th, 16:30 - 18:30

Rosalind Eeles, Genetic Predispnsion to Prostate Cancer and Application to Targeted Screening
Samir Hanash, Systems Approaches to Blood Based Cancer Biomarkers
Kerri Winters-Stone, The Role of Physical Activity in Cancer Prevention and Survival
Elio Riboli, 20 Years of EPIC Cohort Study: News and Next Steps

SESSIoN 1  –  INTEGRATIVE RADIOTHERAPY                           23rd, 08:45 - 11:30
SESSIoN 2  – DRuGGING  THE  CANCER  GENoME                              23rd, 11:30 - 16:30
SESSIoN 3  – INNo VATIVE  ANTI-C ANCER  TARGETs                         24th, 08:00 - 11:30
SESSIoN 4  – ANTI-CANCER  IMMuNo THERAPY                                  24th, 11:30 - 16:00
SESSIoN 5  – PREVENTIoN  &  EARL y CANCER  DETECTIoN               24th, 16:30 - 18:30
SESSION 1 – INTEGRATIVE RADIOTHERAPY

23rd, 08:45 - 11:30

Dan G. Duda, Combining Stroma-Targeted Therapies with Radiation to Prevent Resistance
Jens Overgaard, Intratumoral Heterogeneity: Hypoxia and Radiotherapy
Gillies McKenna, The Tumour Microenvironment in Radiotherapy: Approaches to the Problem
Jürgen Debus, Hitting the Target

SESSION 2 – DRUGGING THE CANCER GENOME

23rd, 11:30 - 16:30

William Hahn, Functional Genomics, Experimental Models and Cancer
David Gonzalez, Molecular Stratification of Cancer in the Clinical Setting
Brian Huntly, Altered Transcriptional and Epigenetic Control in Acute Myeloid Leukemia: Mechanisms and Novel Therapeutics
Mathew Garnett, Discovery of Drug Sensitizing Genotypes in Cancer Cells
Mario Capecchi, Modeling Human Cancers in the Mouse
Ugur Sahin, Towards Individualized Immunotherapy
Klaus Pantel, “Liquid Biopsy” Current Status and Future Perspective
Nils Cordes, Beyond the CENTRIC Trial – Integrative Targeting for Tumor Therapy Sensitization

SESSION 3 – INNOVATIVE ANTI-CANCER TARGETS

24th, 08:00 - 11:30

Rolf Bjerkvig, Adaptive Mechanisms to Anti-Vascular Therapy
Patrick Wen, Novel Targets and Strategies in Gliomas
W. K. Alfred Yung, Targeting PI3K Pathway Resistance in Glioblastoma
Thomas Würdinger, Novel Therapeutic Interventions in Glioblastoma
Stefan Pfister, New Therapeutic Targets in Childhood Brain Tumors
Matthias Mann, The Modern MS-Based Proteomics Toolbox and its Application in Cancer

SESSION 4 – ANTI-CANCER IMMUNOTHERAPY

24th, 11:30 - 16:00

Robert Schreiber, Cancer Immunodetector and a Genomics Approach to Cancer Immunotherapy
Hans-Georg Ramsemmen, Towards Personalized Immunotherapy of Cancer
Cornelis Melief, Towards more Efficient Immunotherapy of Established Lesions Caused by High-Risk HPV
Steve Feldman, Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells
George Prendergast, Cancer Immunomodulation: IDO Pathway and its Therapeutic Correction
Klaus Bosslet, Manipulation of the Tumor Micro Environment by Depletion of Tumor Associated Macrophages
Gail Lewis Phillips, Multiple Strategies for Targeting HER2-Positive Breast Cancer

SESSION 5 – PREVENTION & EARLY CANCER DETECTION

24th, 16:30 - 18:30

Rosalind Eeles, Genetic Predisposition to Prostate Cancer and Application to Targeted Screening
Samir Hanash, Systems Approaches to Blood Based Cancer Biomarkers
Kerri Winters-Stone, The Role of Physical Activity in Cancer Prevention and Survival
Elio Riboli, 25 Years of EPIC Cohort Study: News and Next Steps